



Freedom of Information request & West Norfolk CCG response

WN-2016-00074 – CCG's Formulary

1. On what date was Vedolizumab (for us in relation to Crohn's Disease) first added to the [Norfolk Formulary](#)?

November 2015

2. What restrictions (if any) does the CCG's formulary have in place in relation to the number of individual biologic drugs in use/on formulary at any one time for use within Rheumatoid Arthritis?

No restrictions

3. What restrictions (if any) does the CCG's formulary have in place in relation to the number of individual biologic drugs in use/on formulary at any one time for use within Psoriatic Arthritis?

No restrictions

4. Finally, could you provide a link/attach to your response the latest versions of your patient pathways for Crohn's Disease and Psoriatic Arthritis?

The pathway for Crohn's Disease has been attached.

The pathway for Psoriatic Arthritis is still in development.